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List of abbreviations 
 
ABL1   c-abl oncogene 1, receptor tyrosine kinase 
AP   accleration phase 
ATM   ataxia teleangiectasia mutated 
BC   blastic crisis 
BCR   breakpoint cluster region 
BCR-ABL DF  dual fusion BCR-ABL1 FISH probe 
BCR-ABL SF  simple fusion BCR-ABL1 FISH probe 
CCyR   complete cytogenetic response (0/20 metaphase Ph+) 
CEP8   FISH probe specific for the centromeric region of chromosome 8 
CHR   complete hematologic response 
CML   chronic myeloid leukemia 
CMR   complete molecular response (≤ 0,01 or 0,0032% BCR-ABL1/ABL1 ratio) 
CP   chronic phase 
DAPI   4',6-diamidino-2-fenilindol 
ELN   European Leukemia Net 
e13a2   BCR-ABL1 breakpoint corresponding to M-Bcr (b2a2) 
e14a2   BCR-ABL1 breakpoint corresponding to M-Bcr (b3a2) 
e19a2   BCR-ABL1 breakpoint corresponding to µ-Bcr, producing p230 protein 
e1a2   BCR-ABL1 breakpoint corresponding to m-Bcr, producing p190 protein 
FISH   fluorescence in situ hybridisation 
MCyR   major cytogenetic response (0-7/20 metaphase Ph+) 
mCyR   minor cytogenetic response (8-13/20 metaphase Ph+) 
minCyR   minimal cytogenetic response (14-19/20 metaphase Ph+) 
MMR   major molecular response (≤ 0,1% BCR-ABL1 on the international scale) 
NCyR   no cytogenetic response (20/20 metaphase Ph+) 
OCT1   organic cation transporter 1 
PCR   polimerase chain reaction 
PCyR   partial cytogenetic response (1-7/20 metaphase Ph+) 
Ph1   Philadelphia-chromosome 
RB1   retinoblastoma 1 
ROC-analysis  „receiver operating characteristic” analysis 
RQ-PCR  real time, quantitative PCR 
RT-PCR  reverse transcription PCR 
SD-1   a cell line derived of a patient with Ph+ ALL (B-lymphoblastic cell line) 
XPB   xeroderma pigmentosum B 
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Introduction 
 
 
Chronic myeloid leukemia (CML) may be regarded as a paradigm of modern 
oncology. CML was desribed as the first leukemia 165 years ago. The first cytogenetic 
abnormality associated with a malignant disease – the Philadelphia-chromosome (Ph-
chromosome) – is related to CML. Gene fusion resulting in the BCR-ABL1 gene producing a 
protein with abnormal tyrosine kinase function was recognized as a vital pathogenetic factor 
in malignant disease for the first time in CML patients. The discovery of the BCR-ABL1 
protein opened a new chapter in oncotherapy, CML was the first disease where molecularly 
targeted therapy produced groundbreaking results. Also, CML was the first disease that 
required a complex molecular and cytogenetic treatment response monitoring strategy. 
At the turn of the millenium the first tyrosine kinase inhibitor, imatinib appeared and 
brought never before seen results in the treatment of CML; 85% 8-year overall survival, and 
only 8% progression that in the majority of cases occurs in the first three years of therapy. 
Not all patients benefit from imatinib therapy. 20-25% of patients do not show the 
desired therapeutic response, 8-10% is intolerant to the drug. For them the favorable survival 
is not guaranteed, which defines a need for more effective tyrosine kinase inhibition. Today 
two second generation tyrosine kinase inhibitors are already available for CML patients. Both 
provide more rapid and deeper therapeutic responses than imatinib and studies regarding their 
long-term survival benefits are underway. 
Essential questions remain regarding imatinib treatment of CML. Which method leads 
to the earliest recognition of patients for whom imatinib doesn’t appear to be potent enough? 
Presently, the method of choice is the assessment of the depth of therapeutic response at 
specific timepoints of treatment. This assessment is performed by bone marrow karyotyping, 
real time quantitative polymerase chainreaction (RQ-PCR), or fluorescence in situ 
hybridization (FISH). 
It is important to identify the factors leading to resistance. The recognition of these 
may help designing effective treatment protocols so the survival of imatinib resistant patients 
may be improved. 
It is still unclear how the different translocation breakpoints of BCR-ABL1 influence 
the observable phenotype of the disease. The breakpoints result in different transcripts, and 
thus different proteins, and altough these differ in their in vitro transformation potential, the 
prognostic significance of this difference is currently unknown. 
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It is widely accepted that the BCR-ABL1 translocation is necessary and sufficient for 
the development of CML, however, a few observations indicate that the translocation may be 
a secondary cytogenetic event appearing due to previous genetic instability. This possibility 
bears huge significance since current treatment strategies in CML focus on the selective 
destruction of only the BCR-ABL1 positive cells. 
 
 
Aims 
1. Determining the role of FISH in monitoring CML patients. 
 
2. Determining the benefits of automated FISH analysis compared to manual FISH 
investigation regarding monitoring treatment in CML patients. 
 
3. Investigation of the genetic and molecular background of imatinib resistance. 
 
4. Investigation of the prognostic significance of the rare types of BCR-ABL1 breakpoints in 
CML. 
 
5. Demonstration of the interpretation difficulties posed by additional citogenetic aberrations 
in CML by investigating a patient and his family. 
 
6. Determining the significance of secondary aberrations appearing simultaneously in 
Philadelphia-positive and negative cells by investigating two CML patients. 
 
 
Materials and methods 
 
Samples 
The thesis was based on 2900 bone marrow and peripheral blood samples of 356 CML 
patients our lab recieved between 2003 and 2011 for routine diagnostics mostly from Pécs, 
Szekszárd, Szombathely, Zalaegerszeg, Tatabánya and Veszprém. 
 
 
 5 
Karyotyping 
The chromosome banding was performed using G-banding after 24 or 48 hours of 
culturing bone marrow samples, or using direct bone marrow preparations without culturing. 
At least 20 metaphases were analyzed, whenever possible. The karyotypes were described 
using the International Human Cytogenetic Nomenclature. 
 
Fluorescence in situ hibridisation 
 Commercially available dual-colour simple and dual fusion probes (BCR-ABL SF and 
BCR-ABL DF, Vysis Inc.) were used for FISH analysis. When manual investigation was 
performed, 200 cells were analyzed. The cutoff for positivity was determined based on 
samples of healthy adults (mean + 2 SD). For FISH analysis, peripheral blood or bone 
marrow samples were used. 
 The automated FISH analysis was performed using Metafer 4.0, a commercially 
available image capture and analysis software and a motorized, epifluorescent Zeiss 
Axioplan2ie MOT microscope. 
 Consecutive FISH investigations were performed using commercially available probes 
specific for the centromeric region of chromosome 8 (CCEP8, Vysis Inc.) as a first step. 
Then, images of cells were captured with Metafer 4.0, and after the removal of FISH probes, 
rehibridisation was performed using the BCR-ABL DF probe. The cells were relocated based 
on the images captured previously, thus, the clonal relationship of trisomy 8 and BCR-ABL1 
translocation was determined. 
 
PCR investigations 
 PCR investigations were carried out using primer combinations recommended by the 
Europe Against Cancer program after reverse transcription. Nested PCR was used for the 
qualitative assessment of BCR-ABL1 expression, the quality of RNA was controlled with 
PCR reactions using ABL1 exon 2 and 3 primers. 
 Quantitative BCR-ABL1 investigations were performed using a commercially 
available kit (BCR-ABL FusionQuant, Ipsogen, CT, USA) according to the protocoll 
recommended by the manufacturer, following reverse transcription. Our lab took part in a 
national standardisation program that provided an International Conversion Factor of 0.9253. 
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ABL1 kinase domain mutation analysis 
 Analysis of the ABL1 kinase domain for point mutations was performed by 
bidirectional direct sequencing using BigDye 1.1 cycle sequencing kit and ABI PRISM 310 
(Applied Biosystems, CA, USA) genetic analyzer. The labeling occurred after reverse 
transcription and a heminested selective PCR amplification of the ABL1 kinase domain 
corresponding to BCR-ABL1. 
 
 
 
Results and discussion 
 
1. Determining the role of FISH in monitoring CML patients 
 
 A potential role of FISH in monitoring CML patients may be to complement the 
established prognostic information provided by bone marrow karyotyping. To reveal this 
possible role, FISH results of 150 peripheral blood samples of chronic phase CML patients 
were compared to the results of contemporaneus bone marrow karyotyping. In cases of 
complete cytogenetic response (CCyR, 0 Ph+ metaphases out of 20) FISH showed BCR-ABL1 
positivity in 0 – 13.0% of cells (mean: 5.0%). Based on reciever operatig characteristic (ROC) 
analysis, the optimal cutoff value of FISH for determining CCyR was 7%. Using this cutoff 
FISH predicted the presence of CCyR with 81% sensitivity and 84% specificity. 
 Since CCyR and partial cytogenetic response (PCyR, 1 –7 Ph+ metaphases out of 20) 
are overlapping categories, the relationship of FISH and major cytogenetic reponse (MCyR), 
i.e. CCyR or PCyR was also investigated. Using a cutoff value of 15%, FISH performed on 
peripheral blood samples predicted the presence of MCyR with 95% sensitivity and 96% 
specificity, when BCR-ABL SF probe was used. 
120 peripheral blood samples were used as above when the performance of FISH with 
BCR-ABL DF probe was investigated. The optimal cutoff value was 1% for CCyR, which 
provided 91% sensitivity and 96% specificity. MCyR was predicted using 15% cutoff value 
with sensitivity and specificity of 99% and 90%, respectively. 
Results of karotyping of RQ-PCR also showed strong correlation. 1% BCR-
ABL1/ABL1 cutoff predicted the presence of CCyR with 98% specificity, but with only 82% 
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sensitivity. The relationship of MCyR and 10% RQ-PCR was characterized with 95% 
specificity and 90% sensitivity.  
The gold standard of monitoring treatment of CML patients is bone marrow 
karyotyping. This method requires bone marrow aspiration, and has a relatively high limit of 
detection; 14% of Ph-positivity can be detected with 95% confidence. Complete and partial 
cytogenetic responses should be considered combined, since in cases of low level Ph-
positivity amounting to a few percent, there is a considerable overlap between the two 
cathegories. 
The role of the sensitive real-time quantitative (RQ-PCR) is rapidly expanding as a 
tool of monitoring CML patients. RQ-PCR is capable of demonstrating residual leukemia as 
low as 10-4-5. Several reports show strong correlation with karyotyping, however, the results 
are based on different biological backgrounds. The correlation with karyotyping becomes 
strong only with the advancement of treatment; cytogenetic cathegories cannot be determined 
with confidence when CCyR is not reached. 
FISH is a cell-based method that can be performed even using peripheral blood 
samples. Its sensitivity is lower than that of RQ-PCR with several orders of magnitude, it 
cannot supplant the latter, the limit of detection is approximately 2 – 9%; the exact value 
depends on the type of probe used. The exact role of FISH in treatment monitoring of CML 
patients is not clarified in international recommendations. 
 Our results indicate that FISH may be used to determine the presence of MCyR and 
CCyR in CML patients. According to the recommendation of the European Leukemia Net, 
treatment response is suboptimal, if MCyR is not reached by 6 months, or CCyR is not 
reached by 12 months of treatment. Treatment failure is asserted when MCyR is not reached 
by 12 months, or CCyR is not achieved by 18 months. The loss of MCyR or CCyR is an 
adverse prognostic information regardless of the timepoint it occurs. The above represent the 
situations when in the case of unsuccessful or unavailable karyotyping FISH may be used to 
determine the level of cytogenetic response. The presence of MCyR and CCyR may be 
asserted with higher sensitivity based on FISH results compared with RQ-PCR, thus a more 
prudent declaration of treatment failure potentially leading to a more expensive, or more 
dangerous therapies may be possible. 
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2. Comparing automated and manual FISH analysis 
 
 We have set an automated microscope system for the analysis of FISH using simple 
fusion BCR-ABL1 probe, and compared the results of automated analysis with the results of 
manual investigation. First, we trained the automated system using positive and negative 
samples to detect cells and FISH spots of red and green fluorescence. Cell detection was 
hampered mostly by clumped cells that were recognized as single cells. The rejection of these 
cells from further analysis was easily achieved based on geometrical parameters, after 
rejection, cell detection was achieved with 99.9% specificity and 88.7% sensitivity. 
 The detection of red and green FISH spots was performed with 81% and 85% 
precision, respectively. Incorrect spot detection led to unexpected number of spots within 
cells. After rejecting cells with an incorrect number of spots the precision of spot detection 
was 99.6%. 
 After the above mentioned rejections, the discrimination of positive and negative cells 
was based on the shortest distance between red and green FISH spots. The false positivity and 
negativity of automated analysis amounted to 6.7% and 5.5%, respectively. The same values 
of manual analysis were 5.8% and 2.7%, respectively. 
 Next, manual and automated FISH analysis performed on peripheral blood samples of 
18 CML patients were compared. Samples of patients with a low residual disease 
approximating the limit of detection were chosen. Manual analysis was performed by three 
investigators independently. 
Automated and manual results showed strong correlation (R2 = 0.99), the mean of 
difference was only 3.7%. Reproducability of the automated analysis proved to be superior to 
mannual analysis. The results of the three investigators differed in a range of approximately 
20%, in the case of twelve out of 18 samples this difference led to disagreement regarding 
whether the sample showed positivity surpassing the cutoff value of false positivity or not. 
Automated analysis performed on the same number of cells showed differences only in a 
range of 8%, which corresponds to sampling error. Out of the 18 samples investigated, only 7 
demonstrated ambiguity regarding positivity. 
Based on our results it can be concluded that automated FISH analyis is possible with 
adequate precision. Although false positivity and negativity are not improved compared to 
manual analysis, interobserver variability is eliminated, thus, precision of the analysis is 
improved even when analysing only 200 cells. Automation makes the increase of analysed 
cells easily possible, the limit of which is set by the hardware capabilities alone. Furthermore, 
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digital images of cells are captured with automated analysis, accomplishing documentation as 
well. Relocation of analysed cells is possible using the coordinates of cells, leading to the 
possibility of combining the analysis with immunophenotyping or additional FISH 
investigations. 
 
 
3. Factors of imatinib-resistance in CML 
 
The cytogenetic and molecular factors of imatinib resistance were  investigated in 48 
CML patients. Bone marrow karyotyping, FISH, qualitative and quantitative PCR were 
performed. The parameters observed were compared with similar parameters of 98 patients 
without signs of resistance. 
The type of the Ph-translocation, interstitial deletions neighboring the breakpoints and 
the type of the BCR-ABL1 transcript (b2a2 or b3a2 breakpoints) did not show different 
frequencies in resistant and non-resistant cases, so they do not seem to influence treatment 
responses. 
ABL1 kinase domain point mutations were detected in 29% of resistant patients. A 
broad range of incidence – 21 - 90% – is reported in the literature that is influenced by the 
phase of the disease and the level (i.e. cytogenetic or hematologic) of resistance. In only 13% 
of patients (6/48) could the observed point mutation be held responsible for imatinib 
resistance, since in the other cases, the mutation was detected after resistance commenced. It 
is possible that point mutations were present before the first observation of resistance below 
our limit of detection. However, resistance is defined as the accumulation of a residual 
leukemic clone; a point mutation can hardly be the cause of the lack of treatment response if it 
is present in only a small subset of residual leukemic cells. 
The finding described above is surprising, since ABL1 kinase domain mutations are 
considered to be the most frequent causes of tyrosine kinase inhibitor resistance, although 
several publications suggest that mutations are not directly responsible for resistance, but 
rather are indicators of genetic instability leading to resistance. 
46% (22/48) of patients with resistance showed additional cytogenetic abnormalities 
besides the Ph-translocation. 14/48 cases showed duplication of the Ph-chromosome, 1/48 
case presented with BCR-ABL1 amplification. These frequencies are similar to the ones 
reported in the literature: 7/32 and 2/32, respectively. 
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 In cases with imatinib resistance, clonal evolution and ABL1 kinase domain point 
mutations were observed most frequently, but their causality is ambiguous. In 14 cases no 
cytogenetic or molecular abnormality was detected. Presumably, inadequate treatment 
responses are often invoked by pharmacokinetic factors or lack of adherence to the drug that 
frequently causes mild side effects and needs to be taken every day. 
 
 
4. Prognostic significance of rare BCR-ABL1 breakpoints in CML 
 
Three CML cases were investigated where BCR-ABL1 transcripts of exclusively the 
m-bcr (e1a2) breakpoint were found. Monocytosis was not seen in either case. One of the 
patients recieved imatinib as second-line treatment after having developed accelerated phase 
under interferon treatment, the other two patients were initiated on first-line imatinib 
treatment. All three demonstrated complete hematologic response, however, cytogenetic 
response did not develop in one of them, although progression did not occur during 5 years of 
follow-up. One of the other two patients relapsed after 19 months of treatment, developed 
myeloblastic crisis and succumbed to the disease at 39 months. The third patient shows 
complete cytogenetic response after 3 years of follow-up. 
An additional patient with chronic phase CML was investigated, who was presented 
with BCR-ABL1 transcripts of the µ-bcr (e19a2) breakpoint. Initially, interferon treatment 
was started, later, due to inadequate treatment response, imatinib with increased dose was 
administered. Finally, allogeneic bone marrow transplantation was performed because of the 
occurence of blastic crisis. Complete cytogenetic reponse developed after transplantation, 
however blastic crisis reoccured 5 months later. Although complete cytogenetic reponse was 
achieved with chemotherapy, the patient died due to septic shock. 
The majority of CML patients harbor translocation breakpoints involving the major 
breakpoint cluster region (M-bcr) of the BCR gene leading to the formation of a 210 kDa 
protein. Rarely, in 1% of patients the breakpoint is located in a different region. Alternative 
breakpoints are the m-bcr (e1a2) that is frequent in acute lymphoblastic leukemia and results 
in a 190 kDa protein, and the even more rare µ-bcr (e19a2) that yields a 230 kDa protein. The 
different BCR-ABL1 proteins have divergent transformation potentials in vitro. The exclusive 
presence of m-bcr BCR-ABL1 transcripts in CML is associated with monocytosis and adverse 
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prognosis based on various reports, while the µ-bcr breakpoint is related to an excess of 
neutrophils similar to chronic neutrophilic leukemia and a better prognosis. 
The four cases investigated do not support the above associations between the 
observable phenotype and the rare BCR-ABL1 transcripts. The exclusive presence of the m-
bcr transcript was indeed associated with poor prognosis, since two out of three such patients 
did not achieve CCyR, however, neither patients showed monocytosis. The patient harboring 
the µ-bcr breakpoint died of his disease after suffering multiple blast crises, which does not 
indicate a good prognosis. 
How the same genetic abnormality may lead to different phenotypes is still an 
unresolved question, just like the relationship between the diverse in vitro transformation 
potential of BCR-ABL1 proteins and the difference of phenotypes related to them. 
 
 
5. Interpretation difficulties of cytogenetic aberrations besides the Ph-translocation 
during the follow-up of a CML patient 
 
Bone marrow karyotyping revealed cytogenetic aberrations involving six different 
chromosomes besides Ph-positivity at diagnosis of a 44-year-old man with CML. The 
accumulation of additional cytogenetic abnormalities suggested an aggresive course of the 
disease. After the commencement of imatinib treatment, neutropenia and thrombocytopenia 
occurred leading to the reduction of the dose. Only minor cytogenetic response was observed 
at 8 months of treatment which is considered as suboptimal treatment response. However, 
complete cytogenetic response was attained at 20 months, major molecular response at 60 
months. 
The first follow-up cytogenetic investigation raised the possibility of the constitutional 
nature of the additional cytogenetic aberrations, thus, karyotyping of phorbol acetate (TPA) 
stimulated peripheral blood lymphocytes was performed. The investigation showed Ph-
negativity in all of the cells, however, the formerly observed additional aberrations were 
present in every cell analysed. These aberrations were present in every cell at every 
subsequent cytogenetic analysis as well. 
The karyotyping of peripheral blood lymphocytes of seven family members involving 
three generations of the patient was performed. The three constitutional translocations 
involving the six chromosomes were seen in six family members, two abnormalities were 
seen in two. The presence of all three abnormalities was restricted to the patient. 
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The above findings demonstrate clearly that while FISH and the PCR-based methods 
are targeted tests aimed at the BCR-ABL1 translocation, karyotyping yields information 
concerning the entire genome. The rarely occuring constitutional aberrations may confound 
the prognostic interpretation of secondary cytogenetic alterations. Currently, there is no 
conclusive evidence that constitutional cytogenetic aberrations increase the risk of malignant 
hematological diseases; however, our case illuminates the possibility that genetic instability 
leading to the accumulation of constitutional abnormalities may provide the background for 
the development of the Philadelphia-translocation as well. Fortunately, neither the patient nor 
his relatives demonstrate any sign of escalating constitutional genetic instability, and CML or 
any other malignant disease was not observed in family members. 
 
 
6. The significance of secondary aberrations appearing simultaneously in Philadelphia-
positive and negative cells in two CML patients 
 
Samples of a 50-year-old male and a 40-year-old female patient were investigated. 
Both patients received first line imatinib treatment due to chronic phase CML. The dose was 
reduced temporarily due to cytopenias in both cases. Cytogenetic studies revealed trisomy 8 
in both Ph-positive and Ph-negative cells at 6 and 16 months in the two cases, respectively. 
Only minor cytogenetic response was reached with imatinib treatment in both cases, 
so dasatinib was initiated. Neither patient demonstrated the presence of any ABL1 kinase 
domain mutation during their follow-up. Significant residual disease was seen in both cases 
after temporary cytogenetic improvement at 23 and 27 months of dasatinib treatment, 
respectively. At last follow-up, all three abnormal clones – Ph-positive, Ph-positive and 
trisomy 8, and Ph-negative and trisomy 8 – were present in both cases. 
We investigated the clonal relationship of 8 trisomy and the BCR-ABL1 translocation 
in the samples of the two patients with interphase FISH. The three abnormal clones were 
detectable in both cases starting from a very early point during follow-up. The clones did not 
demonstrate any obvious growth advantage; no trends were observed in their ratios as time 
progressed. 
Both patients were resistant to both imatinib and dasatinib. There is a possibility that 
trisomy 8 developed due to a genetic instability predating the Ph-translocation in both cases. 
This possibility bears major significance: if the genetic instability characteristic of CML cells 
frequently leading to tyrosine kinase inihibitor resistance is not the consequence of the 
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abnormal tyrosine kinase function of BCR-ABL1, but rather develops before the Ph-
translocation, than rapid and selective inhibition of BCR-ABL1 will not achieve protection 
against treatment resistance, not even using more advanced tyrosine kinase inhibitors. The 
identification and targeted therapy of the abnormality predating the Ph-translocation would be 
more beneficial. 
 
 
Summary 
 
1. We determined the potential role of FISH in monitoring the treatment reponse of 
CML patients. The method may lead to assessment of major or complete cytogenetic response 
even using peripheral blood samples. At the early phase of treatment, suboptimal response or 
treatment failure may be determined with greater sensitivity using FISH than RQ-PCR. 
 
2. We demonstrated that the sensitivity and the accuracy of FISH investigation may be 
improved by automated analysis since it provides the significant increase of the numbers of 
investigated cells without increasing manual working hours. Additionaly, automated analysis 
removes interobserver variablity. We characterized the specifications of the automated FISH 
analysis of BCR-ABL1 translocation, which may provide the basis of similar specifications of 
detecting different genetic abnormalities. 
 
3. We investigated the molecular and genetic factors of imatinib resistance. The most 
frequent cause proved to be clonal cytogenetic evolution, ABL1 kinase domain mutations 
were observed with slightly lower incidence compared with what is reported in the literature. 
In several cases we observed that the ABL1 kinase domain mutation is not the cause of the 
imatinib resistance, but rather is the indicator of genetic instability leading to the resistance. 
 
 4. We determined that the rare BCR-ABL1 breakpoints are not associated with an 
obvious, specific prognosis or phenotype. The relationship between the different BCR-ABL1 
transcripts and the phenotype of the disease is still unclear. 
 
 5. We highlighted the difficulties of interpreting constitutional cytogenetic 
abnormalities in the case of a CML patient and his family, and we pointed at potential 
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differential diagnostic difficulties. Our findings also raised the possibility of an underlying 
genetic instability causing the Ph-translocation. 
 
 6. With the thourough investigation of two CML cases, we have found support of the 
theory that the Ph-translocation may be a secondary abnormality in CML. 
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